Plain-English translation of NCT06993974 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called , when added to a standard ulcerative colitis treatment (), can help reduce the inflammation and symptoms of ulcerative colitis more effectively. You would take both medications together for 3 months while researchers track how well the treatment works and whether it's safe.
Ulcerative colitis causes chronic inflammation in the colon and rectum that can seriously affect quality of life. Researchers want to see if this medication could offer patients a better treatment option when added to existing therapies.
You likely qualify if…
You likely don't qualify if…
You would join one of two groups for 3 months: the standard treatment group would take alone, while the other group would take plus the new medication () twice daily. Both groups would likely have clinic visits and possibly colonoscopies to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Egypt
Phase
Testing effectiveness
Sponsor
Alexandria University
Collaborators
Prof. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University., Assoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University.
Enrollment target
~70 participants
Started
May 2025
Primary completion
August 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.